Skip To Content

Error

Sorry, the page you're looking for has moved or doesn't exist.

You can access content using the navigation, searching or visiting the links provided on this page.

Articles and blogs 

February 21, 2022 · Medicare Insights Team
In response to the most recent Workers’ Compensation Medicare Set Aside (WCMSA) Reference Guide, on February 17, 2022, The Centers for Medicare and Medicaid Services (CMS) hosted a webinar to provide a much-anticipated update on non-CMS-approved Medicare Set-Aside (MSA) products. CMS’ John Jenkins, Health Insurance Specialist, reviewed topics including Evidence-Based MSAs, Non-Submit MSAs and Compromise MSA. Read more...
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more...
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more...
February 16, 2022 · Public Policy & Regulatory Affairs Team
Read more...
February 14, 2022 · Medicare Insights Team
On Thursday, February 17, 2022, the Centers for Medicare and Medicaid Services (CMS) will host a Workers’ Compensation Medicare Set-Asides (WCMSA) webinar. During the webinar, CMS will review what’s new with WCMSAs and address questions related to the inclusion of treatments and the application of state rules, re-reviews/amended reviews and more. We also believe CMS will review the recent WCMSA Reference Guide update of Section 4.3 regarding Non-Submit MSAs/EBMSAs. Read more...
February 10, 2022 · Clinical Team
In October 2021, the U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride (HCl) injection - ZIMHI™ (5 mg/0.5 mL) - to treat opioid analgesic overdose. ZIMHI is designed to be administered in the muscle (intramuscular) or under the skin (subcutaneous) using a single-dose, prefilled syringe that delivers 5 mg of naloxone HCl solution. Read more...
February 10, 2022 · Clinical Team
In October 2021, the U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride (HCl) injection - ZIMHI™ (5 mg/0.5 mL) - to treat opioid analgesic overdose. ZIMHI is designed to be administered in the muscle (intramuscular) or under the skin (subcutaneous) using a single-dose, prefilled syringe that delivers 5 mg of naloxone HCl solution. Read more...
February 07, 2022 · Public Policy & Regulatory Affairs Team
On February 3, 2022, the New York Workers’ Compensation Board (WCB) finally responded to the question of, “When will OnBoard Limited Release (OnBoard) go into effect?” Well, pursuant to a series of Subject Number Bulletins the answer is, in three phases, the first of which begins on March 7, 2022. Read more...
February 03, 2022 · Public Policy & Regulatory Affairs Team
Read more...
January 19, 2022 · Public Policy & Regulatory Affairs Team
Read more...
<< Previous      Next >>
Page 2 of 15